Stock TKDA TAKEDA PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Takeda Pharmaceutical Company Limited Deutsche Boerse AG

Equities

TKDA

US8740602052

Real-time Estimate Tradegate
Other stock markets
 06:51:11 2024-06-17 EDT 		5-day change 1st Jan Change
12.3 EUR +2.50% Intraday chart for Takeda Pharmaceutical Company Limited -2.44% -4.76%
02:13pm Ovid Seeks Distance From Epilepsy Drug After Takeda Reports Phase 3 Endpoints Missed -- Pre-Bell Shares Fall MT
02:00pm Takeda Says Phase 3 Soticlestat Trials in Dravet, Lennox-Gastaut Syndromes Missed Primary Endpoints MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The company appears to be poorly valued given its net asset value.
  • The company is one of the best yield companies with high dividend expectations.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 46.58 times its estimated earnings per share for the ongoing year.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
TAKEDA PHARMACEUTICAL COMPANY LIMITED Stock Takeda Pharmaceutical Company Limited
-4.76% 41.3B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+50.70% 791B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+41.41% 630B
B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.77% 328B
B-
ABBVIE INC. Stock AbbVie Inc.
+8.79% 298B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.70% 246B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+0.12% 225B
A+
NOVARTIS AG Stock Novartis AG
+10.24% 218B
B-
AMGEN INC. Stock Amgen Inc.
+3.68% 160B
C+
PFIZER, INC. Stock Pfizer, Inc.
-4.38% 156B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. TKDA Stock
  5. Ratings Takeda Pharmaceutical Company Limited